Gunning For A Cure 2019

Gunning For A CureGunning for a Cure on February 16 is an annual sporting clays competition designed to raise funds for prostate cancer research at Tulane Cancer Center. Our mission is to improve the health of men by discovering the means to better treat prostate cancer, while ultimately aiming to develop a cure for those with advanced disease. Gunning for a Cure hits this target through an annual skeet shooting competition.  All proceeds from this event go directly to Dr. Sartor’s Prostate Cancer Research Fund at Tulane Cancer Center to assist him and his colleagues in accomplishing their goal of curing prostate cancer. Dr. Sartor is a world-renowned prostate cancer expert and the only medical oncologist specializing in prostate cancer in the state of Louisiana.

For more information visit: http://www.gunningforacure.org/

What To Expect

Our exclusive skeet course winds through the beautiful Stella Plantation and changes each year to offer a 1st class shooting experience. After the shoot enjoy a tasty luncheon, our annual 3-gun raffle, great auction items, and activities for the whole family!

About The Research

Between 2010-2013, the U.S. Food and Drug Administration approved six new drugs for the treatment of advanced prostate cancer.  Dr. Sartor played a lead role in the development of two of these drugs and served in an advisory role for two others.  This is unprecedented progress, as these are the first new treatment options offering hope for men with advanced disease since 2004, and they were only possible through large, multi-institutional clinical research trials.

Because of the vital importance of novel treatment options like these, Dr. Sartor zealously focuses much of his time on better understanding advanced prostate cancer and the development of new drugs that make a difference for patients with this disease.  Additionally, Dr. Sartor and his team of collaborators, including basic researchers and physician scientists at Tulane, LSU, and other institutions, are trying to better understand the genetics of prostate cancer in more details.  The project involves the collection of clinical data and complex genetic testing of tissue samples from men with various stages of prostate cancer in an effort to determine what type of genetic defects contribute to cancer risk and progression.  This long-term research project could yield important insights into prostate cancer not only for the subjects and their families, but for a variety of other patients as well.  Though it is an extremely difficult task, there is also an effort to develop a new class of prostate cancer drugs via basic laboratory research. 

Dr. Sartor and his team of collaborators have utilized the $742,000 raised through Gunning for a Cure across a variety of projects, including 1) the collection of clinical data and complex genetic testing of tissue samples from men with various stages of prostate cancer in an effort to determine what type of genetic defects contribute to cancer risk and progression; 2) an effort to develop a new class of prostate cancer drugs via basic laboratory research; and 3) basic laboratory research designed to better understand the molecular underpinnings of cancer.  GFC funds have also been used to purchase basic laboratory materials and reagents required for the team’s laboratory work.

Proceeds from Gunning for a Cure are used to support these and other prostate cancer research initiatives being pursued by Dr. Sartor and his collaborate prostate cancer team.